Dyclonine

Summary

Dyclonine (CHEMBL1201217) is an approved small-molecule topical anaesthetic (ATC R02AD04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R02AD04 (+1 more)
• Clinical trials: 3
• Chemistry: 289.4 Da · C18H27NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201217
Name	Dyclonine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3180
ChEBI	CHEBI:4724
ATC	R02AD04, N01BX02
Molecular formula	C18H27NO2
Molecular weight	289.4
InChIKey	BZEWSEKUUPWQDQ-UHFFFAOYSA-N

SMILES: CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2

IUPAC name: 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one

ChEBI definition: N-Ethylpiperidine in which one of the hydrogens attached to the methyl group is substituted by a 4-butoxybenzoyl group.

Pharmacological roles (ChEBI): topical anaesthetic.

Also known as: Diclonina, Dyclonine, SID11112403, SID50100427, DYCLONINE, Dyclonine (hydrochloride), dyclonine

Parent form; salt/anhydrous children: CHEMBL1200478

Patent coverage: 2,345 distinct patent families (7,785 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 25 (assay-derived). Sample: Nuclear receptor ROR-gamma, Prelamin-A/C, Inositol monophosphatase 1, Muscarinic acetylcholine receptor M4, Alpha-2C adrenergic receptor, Histamine H2 receptor, Thyroid hormone receptor beta, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor M2, D(4) dopamine receptor.

Bioactivity

ChEMBL activities: 23 potent at pChembl ≥ 5 of 27 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P97697	8.89	Potency	1.3	nM	CHEMBL_ACT_4860631
ACHE	6.74	IC50	181	nM	CHEMBL_ACT_18570058
ALDH1A1	6.65	Potency	223.9	nM	CHEMBL_ACT_4123555
LMNA	6.2	Potency	631	nM	CHEMBL_ACT_3624971
SLC6A2	5.64	AC50	2300	nM	CHEMBL_ACT_25145568
CYP2C9	5.6	Potency	2512	nM	CHEMBL_ACT_5061352
CYP2C9	5.6	AC50	2512	nM	CHEMBL_ACT_5991790
CHRM2	5.55	AC50	2813	nM	CHEMBL_ACT_25195401
HRH2	5.5	AC50	3127	nM	CHEMBL_ACT_25114572
Q8K424	5.5	IC50	3200	nM	CHEMBL_ACT_26010468
CYP1A2	5.5	AC50	3162	nM	CHEMBL_ACT_6003447
KCNH2	5.48	AC50	3300	nM	CHEMBL_ACT_25118696
HRH3	5.41	AC50	3900	nM	CHEMBL_ACT_25201053
DRD4	5.39	AC50	4107	nM	CHEMBL_ACT_25127486
HTR2A	5.33	AC50	4725	nM	CHEMBL_ACT_25173805
SLC6A3	5.32	AC50	4820	nM	CHEMBL_ACT_25124524
P15917	5.3	Potency	5012	nM	CHEMBL_ACT_4651674
CYP2D6	5.3	Potency	5012	nM	CHEMBL_ACT_4965832
CYP2D6	5.3	AC50	5012	nM	CHEMBL_ACT_6015248
ADRA2C	5.08	AC50	8400	nM	CHEMBL_ACT_25148465
HRH1	5.07	AC50	8500	nM	CHEMBL_ACT_25213098
ADRA1A	5.01	AC50	9658	nM	CHEMBL_ACT_25138249
P51450	5	Potency	10000	nM	CHEMBL_ACT_4073412

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06729307	PHASE4	NOT_YET_RECRUITING	Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy
NCT07264738	PHASE4	ACTIVE_NOT_RECRUITING	Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study
NCT03352700	PHASE4	UNKNOWN	Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).